Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Philip Kantoff, M.D.


This page shows the publications co-authored by Philip Kantoff and Guru Sonpavde.
Connection Strength

  1. Immunotherapy for castration-resistant prostate cancer. Urol Clin North Am. 2012 Nov; 39(4):465-81.
    View in: PubMed
    Score: 0.532
  2. Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther. 2011 Aug; 11(8):997-1009.
    View in: PubMed
    Score: 0.484
  3. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012 Feb 10; 30(5):507-12.
    View in: PubMed
    Score: 0.125
  4. The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol. 2012 Apr; 61(4):639-47.
    View in: PubMed
    Score: 0.124
  5. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Eur Urol. 2019 01; 75(1):88-99.
    View in: PubMed
    Score: 0.049
  6. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May; 12(5):686-718.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.